tesaglitazar has been researched along with Metabolic Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguilar, E; Asghar, A; Ebenezer, P; Ferder, L; Francis, J; Hu, X; Isidro-Carrión, AA; Liao, J; Reisin, E; Soltani, Z; Zhang, R | 1 |
| Camejo, G; Hultstrand, T; Jacinto, S; Ljung, B; Oakes, ND; Thalén, P; Wallin, B | 1 |
| Fiévet, C; Fruchart, JC; Staels, B | 1 |
1 review(s) available for tesaglitazar and Metabolic Syndrome
| Article | Year |
|---|---|
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Topics: Alkanesulfonates; Animals; Diabetes Mellitus, Type 2; Glycine; Humans; Metabolic Syndrome; Models, Biological; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
2 other study(ies) available for tesaglitazar and Metabolic Syndrome
| Article | Year |
|---|---|
Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats.
Topics: Alkanesulfonates; Animals; Blood Pressure; Glomerular Filtration Rate; Kidney; Kidney Diseases; Metabolic Syndrome; Obesity; Phenylpropionates; PPAR alpha; PPAR gamma; Rats; Rats, Zucker | 2010 |
Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.
Topics: Administration, Oral; Alkanesulfonates; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glucose; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Metabolic Syndrome; Obesity; Phenylpropionates; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Treatment Outcome; Triglycerides | 2005 |